FGF-23 and PTH in Hemodialysis Patients
Launched by MEDICAL UNIVERSITY OF VIENNA · Apr 16, 2020
Trial Information
Current as of June 12, 2025
Completed
Keywords
ClinConnect Summary
Background: The development of sHPT in hemodialysis patients is a common complication which induces an increase in calcification and atherosclerosis. Elevated FGF-23 levels are already found in early stages of chronic kidney disease (CKD) and it has been shown that high FGF-23 levels are associated with the development of cardiovascular disease and increased overall mortality.
Method: In this pilot study a total number of 30 patients on maintenance haemodialysis will be enrolled. The investigator will examine the course of FGF-23 and PTH levels during a single hemodialysis session. In addi...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • \>18 years
- • hemodialysis three times a week
- Exclusion Criteria:
- • Subject is currently enrolled or not yet completed at least 30 days since ending other investigational device or drug trial(s), or is receiving other investigational agent(s)
- • Pregnancy
- • Subject has any kind of disorder that compromises the ability of the subject to give written informed consent and/or to comply with the study procedures
About Medical University Of Vienna
The Medical University of Vienna is a leading research institution dedicated to advancing healthcare through innovative clinical research and education. Renowned for its commitment to excellence in medical science, the university fosters interdisciplinary collaboration among researchers, clinicians, and academic professionals. Its clinical trials encompass a wide range of medical disciplines, aiming to develop cutting-edge therapies and improve patient outcomes. With state-of-the-art facilities and a strong emphasis on ethical standards, the Medical University of Vienna is at the forefront of transforming scientific discoveries into practical applications that enhance global health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Vienna, , Austria
Patients applied
Trial Officials
Rainer Oberbauer, MD, PhD
Principal Investigator
Head of the department of Nephrology and Dialysyis of the MUV
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials